Skip to content
PoliticalRepoPoliticalRepo

Person

Official portrait of Rep. Amodei, Mark E. [R-NV-2]

Rep. Amodei, Mark E. [R-NV-2]

United States · Official source

Memberships

  • R · R · present
  • · House of Representatives · present

Votes

Browse all 3,360 votes

Showing the 24 most recent votes of 3,360. Browse the full list

Records

Browse all 1,699 records
Bill· HRH.R. 9310 (119th)open

Department of Homeland Security Appropriations Act, 2027

United States · United States Congress · 12 June 2026

Department of Homeland Security Appropriations Act, 2027 This bill provides FY2027 appropriations for the Department of Homeland Security (DHS). Specifically, the bill provides appropriations to DHS for Departmental Management, Intelligence, Situational Awareness, and Oversight, including the Office of the Secretary and Executive Management; the Management Directorate; Intelligence, Analysis, and Situational Awareness; and the Office of Inspector General. In addition, the bill provides appropriations for Security, Enforcement, and Investigations, including U.S. Customs and Border Protection, U.S. Immigration and Customs Enforcement, the Transportation Security Administration, the U.S. Coast Guard, and the U.S. Secret Service. The bill provides appropriations for Protection, Preparedness, Response, and Recovery, including the Cybersecurity and Infrastructure Security Agency, and the Federal Emergency Management Agency (FEMA). The bill provides appropriations for Research, Development, Training, and Services, including U.S. Citizenship and Immigration Services, the Federal Law Enforcement Training Centers, and the Science and Technology Directorate. The bill also sets forth requirements and restrictions for using funds provided by this and other appropriations acts.

Bill· HRH.R. 8300 (119th)referred

Swalwell Act

United States · United States Congress · 15 April 2026

Bill· HRH.R. 8205 (119th)open

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

United States · United States Congress · 6 April 2026

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Bill· HRH.R. 8007 (119th)referred

SILVER Act

United States · United States Congress · 19 March 2026

Showing the 24 most recent records of 1,699. Browse the full list